Andersson, P B <br/><br/>
How should we proceed with disease-modifying treatments for multiple sclerosis?  [electronic resource] 

 -  Lancet (London, England)  Mar 1997 
 - 586-7 p.  digital 
<br/><br/> Publication Type: Comment; Journal Article 
<br/><br/><label>ISSN: </label>0140-6736 
<br/><br/><label>Standard No.: </label>10.1016/S0140-6736(05)61562-0  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Clinical Trials as Topic<br/>Disease Progression<br/>Glatiramer Acetate<br/>Humans<br/>Immunoglobulins, Intravenous--therapeutic use<br/>Immunosuppressive Agents--therapeutic use<br/>Interferon beta-1a<br/>Interferon beta-1b<br/>Interferon-beta--therapeutic use<br/>Multiple Sclerosis--immunology<br/>Peptides--therapeutic use